BMS readies nivolumab for melanoma filing

Share this article:
BMS readies nivolumab for melanoma filing
BMS readies nivolumab for melanoma filing

Bristol-Myers Squibb is moving forward with its FDA filing of PD-1 Opdivo (formerly known as nivolumab) for patients with advanced melanoma who have been previously treated with the BMS drug Yervoy. The company announced Thursday that it expects to file by the third quarter and will be using data from its Phase-III Checkmate-037 clinical trial.

The PD-1 drug class works by neutralizing a cancer cell's ability to hide from the immune system.

The news was somewhat expected, since the company announced in June that it was cutting the clinical trial short because patients were doing so well with the drug, but ISI analyst Mark Schoenebaum wrote in a Thursday analysis that the move from clinical trial to filing was faster than the mid-2015 filing date he had anticipated.

The announcement still puts the company behind Merck, whose PD-1 pembrolizumab has a looming October FDA review date, but Schoenebaum notes that the lead may be short-lived, since BMS is expected to have data about an Opdivo-Yervoy combination later this year. The analyst writes that a successful blend “will rapidly become standard of therapy and will likely overtake MRK's pd-1 in this setting.”

Approvals would add shine to Opdivo's legacy, but the longer immuno-oncology game shows a tighter competition among BMS, Merck, Roche and AstraZeneca, with the key PD-1 indication being lung cancer.

Leerink analyst Seamus Fernandez wrote in a Monday research note that his firm trimmed $2 billion from its projected BMS 2025 immuno-oncology sales, while also upping its estimates for Merck's 2025 take of the immuno-oncology market by just over $1 billion. Fernandez is still optimistic about Bristol-Myers's IO portfolio, but tied his firm's brightened Merck outlook to pembrolizumab's potential to be a backbone agent for several tumors when used in tandem with other drugs, including BMS's Yervoy.

BMS is also pursuing multiple tumor types for its PD-1, including non-small cell lung cancer and renal cell carcinoma.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...